Clinical Trial Update: Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children [Phase 1]

View source ↗

Summary

Phase 1 study assessing the infectivity, safety, and immunogenicity of the RSV vaccine RSV 6120/∆NS2/1030s in RSV-seropositive children and RSV-seronegative inf…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• RSV 6120/∆NS2/1030s

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: RSV Infection | Phase 1 | Status: COMPLETED | Results posted: 2023-08-03